Promising, but still at an early stage

Researchers from KU Leuven and UZ Leuven have published new results on two experimental drugs against soft tissue sarcoma: ecubectedin and PM54Both are closely related to trabectedin (Yondelis), a drug already used today for advanced sarcoma when previous chemotherapy has not been sufficiently effective.

This research was carried out in the laboratory, using mouse models into which human tumour tissue had been implanted. It is therefore explicitly preclinical research: an important intermediate step, but not yet a treatment available to patients.

The researchers tested six tumour models, divided across four subtypes. For the more “complex” sarcomas, leiomyosarcoma and dedifferentiated liposarcoma, the effect was modest and comparable to existing drugs. The most striking result was seen in the two so-called translocation-driven sarcomas: ssynovial sarcoma and the rare and aggressive CIC-rearranged sarcoma. In these two cases, the new drugs inhibited or reduced the tumours markedly more strongly than trabectedin. In the CIC-rearranged sarcoma, the tumour even shrank noticeably, and in synovial sarcoma, stabilisation persisted for several weeks after the last dose.

For now, this is mainly encouraging fundamental research that opens the door to further study. The drugs are still in the early phases of clinical trials in humans, and it is not yet known whether, and in whom, they will ultimately be effective and safe. It is therefore not a reason for concrete expectations in the short term, but it is a development that we, as a community, will continue to follow with interest.

That this work comes from a Belgian laboratory underlines how important sarcoma research close to home is. It was made possible in part by patients who donated tissue for scientific research.

More information paper

---------------------------
Source: Gorgels et al., Cancer Research Communications (2026), open access — DOI 10.1158/2767-9764.CRC-26-0377. The study was partly funded by PharmaMar, the developer of these drugs.

Translocation-driven sarcoma:
a tumour driven by one specific DNA error: two pieces of chromosome incorrectly join together, forming an abnormal “fusion gene” that drives cancer growth. This contrasts with “complex” sarcomas, which arise from many different, scattered chromosomal abnormalities. Tumours that depend on a single central error often prove more sensitive to drugs that disrupt precisely that gene transcription process.